NGENF - NervGen Pharma starts dosing in early-stage nerve damage treatment study

NervGen Pharma (NGENF) announces that the first subject has been dosed with nerve damage treatment NVG-291 in the company's Phase 1 clinical trial in healthy volunteers.The study, conducted in healthy subjects, is a two-part, triple-blind, randomized, placebo-controlled, first-in-human study.Part one of the study is the single ascending dose portion of the trial and will be conducted in females. Part two of the study is the multiple ascending dose portion of the trial and will be conducted in post-menopausal females.The primary objective of the trial is to evaluate the safety, tolerability, and pharmacokinetics of NVG-291.The company also plans to initiate Phase 2 trials in spinal cord injury and multiple sclerosis with each of these trials planned to start in 2022.

For further details see:

NervGen Pharma starts dosing in early-stage nerve damage treatment study